Methylene blue in place of acridine orange as a photosensitizer in photodynamic therapy of osteosarcoma.
Methylene blue in place of acridine orange as a photosensitizer in photodynamic therapy of osteosarcoma.
复制标题
DOI：
--
复制
发表时间：
2008-05
期刊：
影响因子：
2.3
通讯作者：
T. Matsubara;K. Kusuzaki;A. Matsumine;H. Satonaka;Ken Shintani;Tomoki Nakamura;A. Uchida
中科院分区：
文献类型：
--
作者：
T. Matsubara;K. Kusuzaki;A. Matsumine;H. Satonaka;Ken Shintani;Tomoki Nakamura;A. Uchida
我们最近建立了一种独特的肌肉骨骼肉瘤治疗模式，将吖啶橙（AO）与光动力手术（PDS）、光动力疗法（PDT）和放射动力疗法（RDT）相结合；在抑制病灶内切除后局部肿瘤复发方面取得了良好的效果。但AO尚未获批临床使用和静脉注射。因此，人们对亚甲蓝（MB）进行了研究，它的化学结构与AO非常相似，并且已经在临床上用于其他疾病的治疗。使用小鼠骨肉瘤 (LM8) 细胞进行的体外研究表明，MB-PDT 具有很强的杀细胞作用，并且 MB 对放射不敏感，在 RDT 中没有显示出效果。体内研究表明，MB 不会在小鼠骨肉瘤组织中特异性积累，并且不会抑制肿瘤生长。在骨肉瘤的 PDS、PDT 和 RDT 中，MB 并不是比 AO 更好的光敏剂。
We recently established a unique therapeutic modality for musculoskeletal sarcomas, combining acridine orange (AO) with photodynamic surgery (PDS), photodynamic therapy (PDT) and radiodynamic therapy (RDT); excellent results were obtained in the inhibition of local tumor recurrence after intralesional excision. However, AO is not yet approved for clinical use and intravenous injection. Therefore, methylene blue (MB), which has a very similar chemical structure to AO and is already in clinical use for other diseases, was investigated. In vitro studies using mouse osteosarcoma (LM8) cells revealed that MB-PDT had a strong cytocidal effect and that MB was not radiosensitive, showing no effect in RDT. In vivo studies showed that MB did not specifically accumulate in mouse osteosarcoma tissue and that it did not inhibit tumor growth. MB is not a better photosensitizer than AO in PDS, PDT and RDT for osteosarcoma.